Try a new search

Format these results:

Searched for:

in-biosketch:true

person:jacobj03

Total Results:

61


ABO/RH type distribution in a large metropolitan public health system [Meeting Abstract]

Jacobson, J L; Sorkin, L M; Ford, K
Background/Case Studies: Many in our public health system have long believed that the racially and ethnically diverse patient population we serve had a higher proportion of both O-positive and O-negative patients than was characteristic of the general US population. Although our blood supplier routinely reported that we purchased a higher percentage of O-positive and O-negative RBCs than their other customers, we did not know the ABO/Rh percentages of our patients. Poor reporting tools limited our ability to extract this type of data from our blood bank computer system. Our system recognized the need to develop better reporting tools.We sought to determine if the long held belief was correct and justified our higher percentage of O-positive and O-negative RBCs. Study Design/Methods: Reports were created to extract ABO/Rh typing results performed on type and screen (T&S) samples performed from January 1, 2017 to December 31, 2018 from our system's blood bank computer system by individual hospital and aggregated system data. The data were analyzed to evaluate our patient ABO/Rh mix to determine if the long held belief was true or false. O-positive and O-negative percentages were also compared between facilities. The percentages of O-positive and Onegative RBC purchases were assessed with regard to the patient ABO/Rh percentages. P values were calculated and evaluated using Student's t test. Results/Findings: From January 1, 2017 to December 31, 2018, 466,444 T&Ss were resulted system-wide, and we purchased 68,853 RBC units. A total of 3.3% of patients were O-negative (facility range, 2.8%-4.8%), and 49.2% were O-positive (facility range, 40.4%-58.3%). Of the RBC units, 15.4% were O-negative and 71.2% were O-positive (overall 86.9% type O). The percentage of type O RBCs purchased far exceeded the percentage of type O patients. The percentage of type O RBC purchases surpassed the percentage of type O patients (p < 0.0007 for 2017 purchases and p < 0.00008 for 2018). The percentage of type O-negative RBC purchases surpassed the percentage of type O-negative patients (p < 0.0039 for 2017 purchases and p < 0.00002 for 2018). A total of 6.9% of patients were Rhnegative. Despite communication to better monitor inventory ordering practices, there was no statistical difference between the percentage of Opositive or O-negative RBC purchases between 2017 and 2018.
Conclusion(s): Contrary to our perception, our patient population has a lower percentage of type O-negative patients (3.3%) than the general US population (6.6%). Our patients are also less likely to be Rh-negative (6.9%; range, 5.3%-13.4%) than the US population (15.0%). Our percentage of type O-positive patients (49.2%) is higher than that of the general US population (37.4%) and more closely resembles the type O-positive rates reported in many African, Central American, and Asian countries from which many of our patients come. Antigen-negative RBCs were only 5.0% of all RBCs purchased and thus cannot alone explain the high type O RBC rate. Our system, including five Level 1 trauma centers, should be able to safely reduce our ordering of O-negative RBCs without negatively impacting patient safety. Access to timely reporting tools should help us drive change
EMBASE:629360885
ISSN: 1537-2995
CID: 4109652

Pathogen reduced plasma products: a clinical practice scientific review from the AABB

Cushing, Melissa M; Pagano, Monica B; Jacobson, Jessica; Schwartz, Joseph; Grossman, Brenda J; Kleinman, Steven; Han, Miah A; Cohn, Claudia S
BACKGROUND:A small body of literature assessing the efficacy and safety of pathogen reduced (PR) plasma has been published. STUDY DESIGN AND METHODS/METHODS:An AABB committee systematically reviewed the literature and graded the clinical trial evidence with the assistance of a GRADE expert. RESULTS:Most studies identified were low quality and had a small sample size; in addition, efficacy and safety were monitored in many different ways making it difficult to quantify therapeutic benefit and risk. The data analyzed in this systematic review showed that pathogen inactivation did not adversely affect the efficacy of S/D or amotosalen plasma transfusions in any patient population studied. In addition, there were no significant safety issues for these patient populations, other than the specific contraindications noted in their respective package inserts. CONCLUSION/CONCLUSIONS:Larger, well-designed trials are needed to further evaluate the efficacy and safety of all of the PR plasma products.
PMID: 31268584
ISSN: 1537-2995
CID: 3968152

The Use of 3- and 4-Factor Prothrombin Complex Concentrate in Patients With Elevated INR

Mohan, Sanjay; Howland, Mary Ann; Lugassy, Daniel; Jacobson, Jessica; Su, Mark K
BACKGROUND: PCC (Kcentra(R)) is an Food and Drug Administration (FDA)-approved 4-factor PCC used for the treatment of warfarin-related coagulopathy (WRC), but it has also been used off-label to treat non-WRC. Three-factor PCC in the form of coagulation factor IX human (Bebulin(R)) has also been used for WRC and off-label to treat non-WRC. It is unclear whether the use of 3- or 4-factor PCCs is effective for the treatment of non-WRC,. OBJECTIVE: Our aim is to characterize the use of 3- and 4-factor PCCs for patients identified with a non-WRC. METHODS: A retrospective analysis of patients who received PCCs for both WRC and non-WRC between January 2012 and July 2015 was conducted. RESULTS: A total of 187 patients with elevated international normalized ratio (INR) who received PCCs were analyzed; 53.9% of patients in the WRC group and 27.7% in the non-WRC group corrected to an INR of 1.3 or less after 3- or 4-factor PCC administration. In those patients with non-WRC and who had underlying liver disease, 3- and 4-factor PCCs reduced mean INR by 0.98 and 1.43, respectively. CONCLUSION: Three and 4-factor PCCs can reduce INR in patients with WRC and in those with non-WRC secondary to liver disease.
PMID: 28468525
ISSN: 1531-1937
CID: 2546612

Addressing the risk of bacterial contamination in platelets: a hospital economic perspective

Li, Justin W; Brecher, Mark E; Jacobson, Jessica L; Harm, Sarah K; Chen, Dorothy; El-Gamil, Audrey; Dobson, Al; Mintz, Paul D
BACKGROUND: Bacterially contaminated platelets (PLTs) remain a serious risk. The Food and Drug Administration has issued draft guidance recommending hospitals implement secondary testing or transfuse PLTs that have been treated with pathogen reduction technology (PRT). The cost implications of these approaches are not well understood. STUDY DESIGN AND METHODS: We modeled incurred costs when hospitals acquire, process, and transfuse PLTs that are PRT treated with INTERCEPT (Cerus Corp.) or secondary tested with the PLT PGD Test (Verax Biomedical). RESULTS: Hospitals will spend $221.27 (30.0%) more per PRT-treated apheresis PLT unit administered compared to a Zika-tested apheresis PLT unit that is irradiated and PGD tested in hospital. This difference is reflected in PRT PLT units having: 1) a higher hospital purchase price ($100.00 additional charge compared to an untreated PLT); 2) lower therapeutic effectiveness than untreated PLTs among hematologic-oncologic patients, which contributes to additional transfusions ($96.05); or 3) fewer PLT storage days, which contributes to higher outdating cost from expired PLTs ($67.87). Only a small portion of the incremental costs for PRT-treated PLTs are offset by costs that may be avoided, including primary bacterial culture, secondary bacterial testing ($26.65), hospital irradiation ($8.50), Zika testing ($4.47), and other costs ($3.03). CONCLUSION: The significantly higher cost of PRT-treated PLTs over PGD-tested PLTs should interest stakeholders. For hospitals that outdate PLTs, savings associated with expiration extension to 7 days by adding PGD testing will likely be substantially greater than the cost of implementing PGD-testing. Our findings might usefully inform a hospital's decision to select a particular blood safety approach.
PMID: 28703862
ISSN: 1537-2995
CID: 2630692

Adoption of System-wide Delivery Goals and Establishment of a Minimum Par Level Dramatically Altered Platelet-Ordering Practices [Meeting Abstract]

Sorkin, E. J.; Ford, K.; Jacobson, J. L.
ISI:000384646400602
ISSN: 0041-1132
CID: 2283882

A System-wide Analysis of Red Blood Cell Unit Purchases Following the Adoption of a Corporate-wide Blood Use Policy and Transfusion Guidelines [Meeting Abstract]

Jacobson, J. L.; Ford, K.
ISI:000384646400603
ISSN: 0041-1132
CID: 2283842

The Cumulative Impact of Prospective Auditing on Decreasing Single-Donor Platelet (SDP) Usage [Meeting Abstract]

Jacobson, J. L.
ISI:000384646400291
ISSN: 0041-1132
CID: 2283852

Estimated Financial Impact of Complying with the FDA Draft Guidance Entitled "Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion" [Meeting Abstract]

Sorkin, E. J.; Jacobson, J. L.
ISI:000384646400584
ISSN: 0041-1132
CID: 2283862

AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections

Heddle, Nancy M; Boeckh, Michael; Grossman, Brenda; Jacobson, Jessica; Kleinman, Steven; Tobian, Aaron A R; Webert, Kathryn; Wong, Edward C C; Roback, John D
Transfusion-transmitted cytomegalovirus (TT-CMV) is often asymptomatic, but certain patient populations, such as very low birth weight neonates, fetuses requiring intrauterine transfusion, pregnant women, patients with primary immunodeficiencies, transplant recipients, and patients receiving chemotherapy or transplantation for malignant disease, may be at risk of life-threatening CMV infection. It is unclear whether leukoreduction of cellular blood components is sufficient to reduce TT-CMV or whether CMV serological testing adds additional benefit to leukoreduction. The AABB CMV Prevention Work Group commissioned a systematic review to address these issues and subsequently develop clinical practice guidelines. However, the data were of poor quality, and no studies of significant size have been performed for over a decade. Rather than creating guidelines of questionable utility, the Work Group (with approval of the AABB Board of Directors) voted to prepare this Committee Report. There is wide variation in practices of using leukoreduced components alone or combining CMV-serology and leukoreduction to prevent TT-CMV for at-risk patients. Other approaches may also be feasible to prevent TT-CMV, including plasma nucleic acid testing, pathogen inactivation, and patient blood management programs to reduce the frequency of inappropriate transfusions. It is unlikely that future large-scale clinical trials will be performed to determine whether leukoreduction, CMV-serology, or a combination of both is superior. Consequently, alternative strategies including pragmatic randomized controlled trials, registries, and collaborations for electronic data merging, nontraditional approaches to inform evidence, or development of a systematic approach to inform expert opinion may help to address the issue of CMV-safe blood components.
PMID: 26968400
ISSN: 1537-2995
CID: 2024572

A System-wide Analysis of Antigen-Negative Red Blood Cell Unit Purchases [Meeting Abstract]

Jacobson, JL; Ford, K
ISI:000369951500498
ISSN: 1537-2995
CID: 1989592